Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: R03AC18

Hirobriz Breezhaler(indacaterol maleate)

Pulmonary Disease, Chronic Obstructive

Marketing Authorisation Holder: Novartis Europharm Limited

EMA Authorisation: 30/11/2009

INN: indacaterol

Indication

Hirobriz Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Hirobriz Breezhaler — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.